We did not collect data on SGLT2 inhibitor use, but the number of potentially affected patients is low, considering only 16/206 had type 2 diabetes and the limited availability of SGLT2 inhibitors in the UK in 2014–2018. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.